Lecture Details - Table of Contents

Sixth International Symposium on Ovarian Cancer and Other Gynecologic Malignancies

Release Date: April 13, 2009| Mar 20-21, 2009, New York, NY

Table of Contents

Intravenous Chemotherapy
Eric L. Eisenhauer

Debate 2: Patients With Recurrent Advanced Ovarian Cancer Should Be Treated With Antiangiogenic Agents in Combination With Chemotherapy: CON
Paul Sabbatini

Debate 3: Secondary Surgical Debulking Is an Acceptable Option in Patients With Recurrent Platinum-Sensitive Ovarian Cancer: PRO
Larry Copeland

Debate 3: Secondary Surgical Debulking Is an Acceptable Option in Patients With Recurrent Platinum-Sensitive Ovarian Cancer: CON
J. Tate Thigpen

Debate 3: Secondary Surgical Debulking Is an Acceptable Option in Patients With Recurrent Platinum-Sensitive Ovarian Cancer: REBUTTAL
Larry Copeland

Clinical Implications of BRCA Testing
Beth Karlan

Overcoming Platinum Resistance
Stephen B. Howell

New Agents for Platinum-Resistant Disease
Robert Coleman

New Developments in the Biology of Endometrial Cancer
Eric L. Eisenhauer

Debate 4: All Patients at High Risk for Ovarian Cancer Should Undergo Routine Screening: PRO
Beth Karlan

Debate 1: Patients With Recurrent Cervical/Endometrial Cancer Should Be Treated With Cisplatin/Paclitaxel: PRO
Krishnansu S. Tewari

Debate 1: Patients With Recurrent Cervical/Endometrial Cancer Should Be Treated With Cisplatin/Paclitaxel: CON
Gillian Thomas

Debate 1: Patients With Recurrent Cervical/Endometrial Cancer Should Be Treated With Cisplatin/Paclitaxel: REBUTTAL
Krishnansu S. Tewari

Debate 2: Vaginal Cuff Brachytherapy Can Be Substituted for Pelvic Radiation Therapy in High-Intermediate–Risk Endometrial Cancer: PRO
Kaled Alektiar

Debate 2: Vaginal Cuff Brachytherapy Can Be Substituted for Pelvic Radiation Therapy in High-Intermediate–Risk Endometrial Cancer: CON
Marcus Randall

Debate 2: Vaginal Cuff Brachytherapy Can Be Substituted for Pelvic Radiation Therapy in High-Intermediate–Risk Endometrial Cancer: REBUTTAL
Kaled Alektiar

Debate 3: Systemic Therapy for All Uterine Cancers Should Be Paclitaxel/Carboplatin: PRO
Matthew Powell

Debate 3: Systemic Therapy for All Uterine Cancers Should Be Paclitaxel/Carboplatin: CON
J. Tate Thigpen

PARP Inhibitors
Deborah K. Armstrong

Novel Antiangiogenic Agents
Robert Coleman

EGFR Inhibitors
Deborah K. Armstrong

Novel Immunotherapy for Ovarian Cancer
George Coukos

HPV Vaccines
Thomas Herzog

Instructions for Participation

To view the streaming Flash Video lectures, click the "View Flash Presentation" link. The latest version of Flash Player is recommended to view the Flash video.
Click here to download Flash Player >>

To download Podcast-ready movies, click "Download Video Podcast," and select "Save target as..." The latest version of Quicktime is recommended to view these movies.
Click here to download Quicktime >>

Read all of the conditions in the Activity Terms box below. You must accept the Activity Terms in order to continue:

Disclaimer
Physicians’ Education Resource presents this resource for educational purposes only. Participants are expected to use their own expertise and judgment while engaged in the practice of medicine. Please consult full prescribing information for any drugs or procedures discussed within.

The views and opinions expressed in these presentations are those of the authors and do not necessarily reflect the views of the sponsor, supporter, or publisher. Although great care has been taken in compiling and checking the information given in this publication to ensure accuracy, the authors and Physicians’ Education Resource and its servants or agents shall not be responsible or in any way liable for the continued currency of the information or for any errors, omissions, or inaccuracies in this publication, whether arising from negligence or otherwise howsoever or for any consequences arising therefrom.

Disclosure of Unlabeled Uses
This reference may contain discussion of published and/or investigational uses of agents that are not approved by the US Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product, or consult the Physician’s Desk Reference.

All rights reserved; for personal use only. No part of this presentation may be translated, reproduced or transmitted by any means or in any type of media form including electronic, mechanical photocopying, recording, broadcasting, or otherwise without prior permission from the publisher.

Software Requirements
The Web pages and Web-based applications require a minimum Web browser of Microsoft Internet Explorer 5.5 or higher, Mozilla Firefox 1.0 or higher, or another compatible Web browser.

If you are not sure of the version of your browser, select Help in the menu bar of your browser, then select About.

PC Users
If you need to upgrade your Web browser, follow one of the links listed below:

Macintosh Users
Compatible Web browsers include

Educational Grants

An educational grant for this activity was provided by:


  1. Eli Lilly and Company
  2. Genentech BioOncology
  4. Centocor Ortho Biotech Inc.
  5. GlaxoSmithKline
  6. Bristol-Myers Squibb
  7. ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company
  8. sanofi-aventis U.S.